A World First in Kidney Transplantation: Nantes Researchers Pioneer Cellular Therapy to Reduce Rejection
Nantes, France – Researchers at the University Hospital of Nantes (CHU de Nantes) are on the cusp of a potential breakthrough in kidney transplantation, initiating a clinical trial that utilizes a patient’s own cells to regulate the immune system and minimize the risk of organ rejection. The innovative approach, dubbed “Eight-Treg,” represents what the hospital describes as a “world first” in improving outcomes for kidney transplant recipients. This advancement comes at a crucial time, as current transplant protocols rely heavily on lifelong immunosuppressant medication, which, while effective, carries significant long-term health risks. The trial is formally launching in conjunction with World Kidney Day on March 10, 2026, alongside a public awareness campaign organized in collaboration with France Rein Pays de la Loire.
Kidney transplantation remains the gold standard treatment for end-stage renal disease, offering patients a chance at a significantly improved quality of life. However, the body’s natural immune response often views the transplanted organ as foreign, triggering a rejection process. To combat this, patients must capture immunosuppressant drugs for the rest of their lives. While these medications prevent rejection, they also weaken the immune system, increasing susceptibility to infections, cancer and other complications like diabetes, and hypertension. The Eight-Treg trial aims to address this challenge by harnessing the body’s own regulatory mechanisms to foster tolerance of the transplanted kidney, potentially reducing the need for high-dose, long-term immunosuppression.
Harnessing the Power of ‘Eight-Treg’ Lymphocytes
The core of the Eight-Treg trial lies in the manipulation of a specific type of immune cell: regulatory T lymphocytes, or Tregs. These cells play a critical role in maintaining immune homeostasis, preventing the immune system from overreacting and attacking the body’s own tissues. Researchers at the CHU de Nantes, in collaboration with the Centre de Recherche en Transplantation et Immunologie Translationnelle (CR2TI), have been studying Tregs for over two decades, with human research ongoing for the past ten years. Their work builds upon foundational discoveries recognized with the 2025 Nobel Prize in Physiology or Medicine, awarded to researchers for their work on regulatory T lymphocytes. The Nobel Assembly at Karolinska Institutet announced the award recognizing the pivotal role of these cells in immune regulation.
The Eight-Treg approach involves extracting a sample of the patient’s blood, isolating the Tregs, and then expanding their numbers in a specialized laboratory setting – the unité de thérapie cellulaire et génique (UTCG) at the CHU de Nantes. This amplification process takes approximately three weeks. The expanded Tregs are then re-infused into the patient shortly before the kidney transplant. The hope is that these boosted Tregs will actively suppress the immune response against the new kidney, minimizing the risk of rejection and allowing for a gradual reduction in immunosuppressant medication. “This cellular therapy represents a particularly innovative new way to achieve immunosuppression, relying on the patient’s own cells,” explained Professor Gilles Blancho, a nephrologist and director of the institute of transplantation in urology-nephrology, and Dr. Diego Cantarovich, a hospital practitioner and co-investigator, in a statement released by the hospital.
A Phased Approach to Evaluating Safety and Efficacy
The initial phase of the Eight-Treg clinical trial is focused on assessing the safety of the therapeutic approach. Researchers are enrolling approximately ten patients receiving kidneys from living donors. These patients will undergo the Treg extraction, amplification, and re-infusion process, and will be closely monitored for any adverse effects. The primary goal of this first phase is to demonstrate that the procedure is safe and well-tolerated. If the safety profile is favorable, subsequent phases will investigate the efficacy of the Eight-Treg therapy in preventing rejection and reducing the need for immunosuppressant drugs. The first results from this pilot study are anticipated within approximately two years.
The CR2TI has a long-standing commitment to advancing the field of transplantation immunology. Their research has been instrumental in understanding the complex interplay between the immune system and transplanted organs. The Eight-Treg trial represents a culmination of years of dedicated research and a significant step forward in the quest for more effective and less toxic immunosuppressive strategies. The potential benefits for kidney transplant recipients are substantial, offering the prospect of improved long-term health and a reduced burden of medication-related side effects.
Understanding the Challenges of Immunosuppression
Current immunosuppressant regimens, while life-saving, are not without their drawbacks. Drugs like cyclosporine, tacrolimus, and mycophenolate mofetil suppress the immune system to prevent rejection, but they also increase the risk of infections, certain types of cancer, and metabolic disorders. These side effects can significantly impact the quality of life for transplant recipients and contribute to long-term morbidity. The Eight-Treg therapy aims to provide a more targeted and personalized approach to immunosuppression, minimizing systemic immune suppression and maximizing the body’s natural regulatory mechanisms. This approach could potentially lead to a more durable tolerance of the transplanted organ, reducing the reliance on lifelong medication.
The development of Eight-Treg also reflects a broader trend in medicine towards cellular therapies, which harness the power of the body’s own cells to treat disease. Cellular therapies have shown remarkable success in treating certain types of cancer, and researchers are now exploring their potential in a wide range of other conditions, including autoimmune diseases and organ transplantation. The CHU de Nantes’ Eight-Treg trial is at the forefront of this exciting field, paving the way for a new generation of immunomodulatory therapies.
Looking Ahead: World Kidney Day and Beyond
The launch of the Eight-Treg clinical trial coincides with World Kidney Day on March 10, 2026, a global event dedicated to raising awareness about kidney disease and promoting kidney health. The CHU de Nantes and France Rein Pays de la Loire are using this opportunity to offer free kidney screenings and educate the public about the importance of early detection and prevention. The trial’s progress will be closely watched by the transplantation community worldwide, as it could potentially revolutionize the way kidney transplants are managed.
The researchers emphasize that this is just the beginning. Further research will be needed to optimize the Eight-Treg therapy and determine its long-term efficacy. However, the initial results are promising, and the potential benefits for kidney transplant recipients are significant. The team at the CHU de Nantes is committed to continuing their work in this field, with the ultimate goal of improving the lives of patients with kidney disease.
The next major milestone for the Eight-Treg trial will be the completion of the initial safety phase and the analysis of the preliminary data, expected in early 2028. We encourage readers to share this article and engage in discussions about the future of kidney transplantation. Your insights and questions are valuable as we follow this groundbreaking research.
Worth a look